HTT

Huntingtin · P42858 · HTT on Sugi Atlas →

2,720,530 patent compounds predicted against HTT, 1,537,877 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Mercaptopurine Anhydrous (SCHEMBL8844)	0.47	7/20
Chloroxine (SCHEMBL3350)	1.00	6/20
Iodoquinol (SCHEMBL3460)	1.00	6/20
SCHEMBL9082	0.47	6/20
Daunorubicin (SCHEMBL3041)	1.00	5/20
Idarubicin (SCHEMBL3750)	1.00	5/20
Clioquinol (SCHEMBL3967)	1.00	5/20
Carubicin (SCHEMBL9552)	1.00	5/20
Daunorubicin (SCHEMBL4444)	0.99	5/20
Daunorubicin (SCHEMBL4445)	0.99	5/20
Carubicin (SCHEMBL4201)	0.98	5/20
Idarubicin (SCHEMBL4838)	0.98	5/20
Benzododecinium (SCHEMBL914)	0.96	5/20
Detorubicin (SCHEMBL8642)	0.81	5/20
Amrubicin (SCHEMBL9140)	0.57	5/20
SCHEMBL6627	0.56	5/20
Adenine (SCHEMBL8111)	0.47	5/20
Aclarubicin (SCHEMBL4532)	0.41	5/20
Aclarubicin (SCHEMBL4533)	0.41	5/20
SCHEMBL1862	1.00	4/20

Clinical trials — most relevant to HTT by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease	PHASE2/PHASE3	RECRUITING
TEsting METformin Against Cognitive Decline in HD	PHASE3	COMPLETED
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD	PHASE1/PHASE2	RECRUITING
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease	PHASE2	COMPLETED
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease	PHASE2	ACTIVE_NOT_RECRUITING
Creatine Therapy for Huntington's Disease	PHASE1/PHASE2	COMPLETED
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod	PHASE2	COMPLETED
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)	PHASE2	COMPLETED
Efficacy and Safety on SOM3355 in Huntington's Disease Chorea	PHASE2	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease	PHASE1	COMPLETED
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease	PHASE1	RECRUITING
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease	PHASE1	RECRUITING
Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease	PHASE1	WITHDRAWN
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease	nan	RECRUITING
Biology-Driven Cognitive Profiling in Huntington's Disease	nan	ACTIVE_NOT_RECRUITING
N- Homocysteinylated Huntingtin in Huntington's Disease	nan	UNKNOWN
Cognitive Assessment Battery (CAB) Beta Study	nan	COMPLETED
A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease	nan	COMPLETED
Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease	nan	ACTIVE_NOT_RECRUITING
Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study	nan	RECRUITING
Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD	nan	UNKNOWN
Development of the Virtual Unified Huntington's Disease Rating Scale	nan	COMPLETED
Accelerated Diffusion MRI for Diagnosis of Hungtington Disease	nan	COMPLETED
Huntington's Disease Young Adult Study 2.0	nan	UNKNOWN
Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders	nan	COMPLETED
Gut Microbiomes in HD	nan	RECRUITING
Study of Biomarkers That Predict the Evolution of Huntington's Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HTT binder may also engage these)

Protein	Name	Similarity
P51112	—	1.000	P51112 →
P42859	—	0.998	P42859 →
Q8BKX6	—	0.995	Q8BKX6 →
O14981	—	0.995	O14981 →
P51111	—	0.995	P51111 →
C5J7W8	—	0.995	C5J7W8 →
P42173	—	0.994	P42173 →
Q80UK8	—	0.994	Q80UK8 →
SMG1	Serine/threonine-protein kinase SMG1	0.994	landscape →
Q5TH69	—	0.994	Q5TH69 →
Q9BVR0	—	0.993	Q9BVR0 →
Q5JWR5	—	0.993	Q5JWR5 →
Q297L2	—	0.993	Q297L2 →
Q9V4Z9	—	0.993	Q9V4Z9 →
Q3UGY8	—	0.993	Q3UGY8 →
Q96N11	—	0.993	Q96N11 →
A1ZBE8	—	0.993	A1ZBE8 →
Q0VF22	—	0.993	Q0VF22 →
Q2NKQ1	—	0.993	Q2NKQ1 →
Q70CQ2	—	0.993	Q70CQ2 →
Q2PFD7	—	0.992	Q2PFD7 →
Q92539	—	0.992	Q92539 →
Q6ZQ93	—	0.992	Q6ZQ93 →
Q9VB98	—	0.992	Q9VB98 →
A7E379	—	0.992	A7E379 →
Q99PI5	—	0.992	Q99PI5 →
Q9VB11	—	0.992	Q9VB11 →
Q756C4	—	0.992	Q756C4 →
E9PVA8	—	0.992	E9PVA8 →
Q6NN85	—	0.992	Q6NN85 →